In-Tether Chiral Center Induced Helical Peptide Modulators Target p53-MDM2/MDMX and Inhibit Tumor Growth in Stem-Like Cancer Cell

Inhibition of the interaction between p53 and MDM2/MDMX has attracted significant attention in anticancer therapy development. We designed a series of in-tether chiral center-induced helical stabilized peptides, among which MeR/PhR effectively reactivated p53. The activation of p53 inhibits cell proliferation and induces apoptosis in both the MCF-7 normal tumor cell line and the PA-1 pluripotent cancer cell line with only minimal cellular toxicity towards normal cells or cancer cell lines with p53 mutations. The in vivo bioactivity study of the peptide in the ovarian teratocarcinoma (PA-1) xenograft model showed a tumor growth rate inhibition of 70% with a dosage of 10 mg/kg (one injection every other day). This is the first application of a stabilized peptide modulator targeting stem-like cancer cell both in vitro and in vivo and provides references to cancer stem cell therapy.

[1]  Chengjie Sun,et al.  Dual In-Tether Chiral Centers Modulate Peptide Helicity. , 2017, Bioconjugate chemistry.

[2]  Xiaodong Shi,et al.  Switching substitution groups on the in-tether chiral centre influences backbone peptides' permeability and target binding affinity. , 2017, Organic & biomolecular chemistry.

[3]  Chengjie Sun,et al.  Investigation of Cellular Uptakes of the In-Tether Chiral-Center-Induced Helical Pentapeptides. , 2016, Bioconjugate chemistry.

[4]  Chengjie Sun,et al.  An In-tether Chiral Center Modulates the Helicity, Cell Permeability, and Target Binding Affinity of a Peptide. , 2016, Angewandte Chemie.

[5]  D. Sekar,et al.  Deciphering the role of microRNA 21 in cancer stem cells (CSCs) , 2016, Genes & diseases.

[6]  G. Lahav,et al.  Cell-to-Cell Variation in p53 Dynamics Leads to Fractional Killing , 2016, Cell.

[7]  M. Todaro,et al.  Dynamic regulation of the cancer stem cell compartment by Cripto-1 in colorectal cancer , 2015, Cell Death and Differentiation.

[8]  P. Horák,et al.  HIF1α Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells , 2014, Molecular Cancer Research.

[9]  Wei-Chun Chang,et al.  Ligand-independent androgen receptors promote ovarian teratocarcinoma cell growth by stimulating self-renewal of cancer stem/progenitor cells. , 2014, Stem cell research.

[10]  C. Ottmann,et al.  Modulators of protein-protein interactions. , 2014, Chemical reviews.

[11]  Hong Sun,et al.  Pluripotent stem cell protein Sox2 confers sensitivity to LSD1 inhibition in cancer cells. , 2013, Cell reports.

[12]  L. Vassilev,et al.  Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy , 2013, Proceedings of the National Academy of Sciences.

[13]  Wei-Chun Chang,et al.  MicroRNA-21 promotes the ovarian teratocarcinoma PA1 cell line by sustaining cancer stem/progenitor populations in vitro , 2013, Stem Cell Research & Therapy.

[14]  Ke Chen,et al.  Understanding and targeting cancer stem cells: therapeutic implications and challenges , 2013, Acta Pharmacologica Sinica.

[15]  Binh Vu,et al.  MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. , 2013, Cancer research.

[16]  B. R. Bowman,et al.  Inhibition of oncogenic Wnt signaling through direct targeting of β-catenin , 2012, Proceedings of the National Academy of Sciences.

[17]  Peter S. Kutchukian,et al.  Structure of the stapled p53 peptide bound to Mdm2. , 2012, Journal of the American Chemical Society.

[18]  Akira Mogi,et al.  TP53 Mutations in Nonsmall Cell Lung Cancer , 2011, Journal of biomedicine & biotechnology.

[19]  J. Sodroski,et al.  Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic , 2010, Proceedings of the National Academy of Sciences.

[20]  M. Frank,et al.  The therapeutic promise of the cancer stem cell concept. , 2010, The Journal of clinical investigation.

[21]  Jindrich Kopecek,et al.  Biorecognition and subcellular trafficking of HPMA copolymer-anti-PSMA antibody conjugates by prostate cancer cells. , 2009, Molecular pharmaceutics.

[22]  Baoli Hu,et al.  Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. , 2007, Cancer research.

[23]  S. Korsmeyer,et al.  Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. , 2007, Journal of the American Chemical Society.

[24]  T. Jacks,et al.  Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.

[25]  J. Dick,et al.  Targeting of CD44 eradicates human acute myeloid leukemic stem cells , 2006, Nature Medicine.

[26]  Wei Gu,et al.  p53 ubiquitination: Mdm2 and beyond. , 2006, Molecular cell.

[27]  E. Vivés,et al.  Tat peptide-mediated cellular delivery: back to basics. , 2005, Advanced drug delivery reviews.

[28]  S. Korsmeyer,et al.  Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix , 2004, Science.

[29]  Michael Berger,et al.  Apoptosis - the p53 network , 2003, Journal of Cell Science.

[30]  W. El-Deiry,et al.  Stabilization of p53 by CP-31398 Inhibits Ubiquitination without Altering Phosphorylation at Serine 15 or 20 or MDM2 Binding , 2003, Molecular and Cellular Biology.

[31]  Yaolin Wang,et al.  Analyses of p53 Target Genes in the Human Genome by Bioinformatic and Microarray Approaches* 210 , 2001, The Journal of Biological Chemistry.

[32]  K. Vousden,et al.  Regulation and function of the p53 tumor suppressor protein. , 2001, Current opinion in cell biology.

[33]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.

[34]  Xin Lu,et al.  RB regulates the stability and the apoptotic function of p53 via MDM2. , 1999, Molecular cell.

[35]  H. Westphal,et al.  Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. , 1992, Cancer research.

[36]  A. Levine,et al.  Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53 , 1983, Molecular and cellular biology.

[37]  Raymond E. Moellering,et al.  Direct inhibition of the NOTCH transcription factor complex , 2010, Nature.

[38]  David P. Lane,et al.  Translating p53 into the clinic , 2010, Nature Reviews Clinical Oncology.

[39]  Jiandong Chen,et al.  Ubiquitous Induction of p53 in Tumor Cells by Antisense Inhibition of MDM2 Expression , 1999, Molecular medicine.

[40]  G. Demers,et al.  Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis , 1996, Nature Medicine.